This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Hemispherx Biopharma Announces Financial Results For The Year Ended December 31, 2012

PHILADELPHIA, March 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the fiscal year ended December 31, 2012. The net loss for 2012's twelve month period (including non-cash effects) was approximately $17,354,000 or $(0.12) per share as compared to a net loss of $9,015,000 or ($0.07) per share for the same period in 2011. This year-to-year increase in net loss of approximately $8,339,000 (93%) was predominantly caused by:

  • the cost of our continued efforts to seek FDA approval of the Ampligen® NDA for Chronic Fatigue Syndrome and preparations for FDA inspections of our New Brunswick, NJ manufacturing facility;
  • the cost of fill, finish and packaging of Alferon N Injection® Work-In-Process inventory along with a related valuation write-down of existing inventory to the lower of cost or market; and
  • the fair value revaluation of the estimated liability related to certain redeemable warrants resulting in a non-cash gain of $85,000 in 2012 as compared to a gain of $2,425,000 for the same period in 2011 for an increased loss of $2,340,000 comparing the two years.

If the non-cash effect of the revaluation of the estimated liability related to the warrants, the inventory write-down and the other non-cash items were excluded from the financial results, the net cash used in operating activities for the twelve month period of 2012 would be approximately $13,136,000 as compared to $10,096,000 for 2011, resulting in an increase in cash used for operations of approximately $3,040,000 or 30%.

Cash, cash equivalents and marketable securities were approximately $43,953,000 as of December 31, 2012 compared to $34,391,000 as of December 31, 2011. Cash, cash equivalents and marketable securities, net of the Margin Loan used for the facility enhancement project at our New Brunswick facility, was approximately $36,902,000 as of December 31, 2012 as compared to $32,696,000 as of December 31, 2011, an increase of approximately $4,206,000 in available cash and marketable securities.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs